Nanoparticulate Drug Delivery Systems for Pseudomonas aeruginosa Infected Lungs in Cystic Fibrosis
![Chart of the drug delivery system for treatment of chronic P.aeroginose infection](https://www.pharmaexcipients.com/wp-content/uploads/2019/03/Graphical-depiction-of-the-suggested-pulmonary-drug-delivery-system-for-the-treatment-of-chronic-P.-aeruginosa-infections-in-CF.png)
Current pulmonary treatments against Pseudomonas aeruginosa infections in cystic fibrosis (CF) lung suffer from deactivation and immobilization of the drug in thick and viscous biofilm/mucus blend, along with the general antibiotic resistance.
The present work suggests pulmonary antibiotic delivery with high load, capable of penetrating the tight mesh of biofilm/mucus as a solution to existing treatment bottlenecks. The potential use of nanoparticulate drug delivery systems to improve the treatment efficiency of lung infections in CF lungs is investigated.
First chapter describes counter-ion complexes as a strategy to enhance drug load and demonstrates its applicability to different antibiotic classes, as well as counter-ions. The second chapter focuses on the drug delivery system development and its optimization via design-of-experiments approach. For the proof-of-concept studies, biodegradable and biocompatible poly (lactic-co-glycolic acid) was suggested and ciprofloxacin was used as model drug substance. MicroJet Reactor (MJR) technology, a precise preparation technique performed under controlled conditions, was employed. Effect of each process parameter was evaluated to ensure quality-by-design. Final chapter is dedicated to physico-chemical and in vitro characterization of the optimized nanoparticles.
Overall, the new established approach offers counter-ion complex loaded PLGA NPs as promising pulmonary nano drug delivery system against P. aeruginosa infections in CF lung.